European Screening Flowchart, AI Risk Assessment Software Study
Newly Updated / European Resource
Just out, DenseBreast-info/Europe’s updated flowchart, European Screening Decision Support Tool.
New Study
Since the publication of the 2007 guideline from the American Cancer Society, one barrier to implementing supplemental screening MRI in high-risk women has been performing risk assessment. With expanding indications for MRI for women at intermediate risk (including many women with dense breasts), MRI capacity has become another major barrier. Just out in Radiology, van Winkel and colleagues in the Netherlands applied AI risk assessment software (Transpara, v. 1.7.0, ScreenPoint Medical) to the mammograms of 2819 women at intermediate risk who underwent screening MRI. An AI threshold that identified the top half of women at higher risk of cancer present identified:
- All 18 (100%) women with mammographically detected cancer
- 24/28 (86%) with MRI-detected cancer
- 13/19 (68%) with mammographically occult cancer
- This could have cut the number of MRI examinations in half (1409) (with AUC 0.72)
Other software tools such as iCAD, Mirai, and Mia have shown similarly good performance in identifying women likely to have mammographically occult cancer who might benefit from screening MRI.